Dr. Pecora on the Pathway Inhibitor Cabozantinib

Video

Dr. Pecora on the Pathway Inhibitor Cabozantinib (XL184)

Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center on the pathway inhibitor cabozantinib.

Dr. Pecora says cabozantinib is an agent that is capable of blocking multiple pathways at the same time. In phase I trials, it has been shown to have activity in a broad array of solid tumors. It will demonstrate that by targeting specific pathways within a cancer cell, you can actually block the growth and, in some cases, kill the cancer cell in diseases that had not been sensitive to other therapies.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,